Regorafenib-Induced Hand-Foot Skin Reaction in an Adolescent.

Area of Science:

• Oncology
• Dermatology
• Pediatric Medicine

Background:

• Regorafenib is a multikinase inhibitor used for cancers like hepatocellular carcinoma, GIST, and colorectal cancer.
• It is also used off-label for pediatric metastatic osteosarcoma, a common bone malignancy.
• Hand-foot skin reaction (HFSR) is a known side effect of regorafenib, but guidelines for pediatric management are lacking.

Observation:

• A case study details an adolescent with metastatic osteosarcoma experiencing grade 3 regorafenib-induced HFSR.
• The patient presented with severe skin reactions on hands and feet.

Findings:

• An effective dose-reduction regimen and treatment plan were implemented.
• This intervention successfully resolved the grade 3 HFSR.
• The patient was able to immediately resume alternative anticancer treatment.

Implications:

• This case highlights a viable strategy for managing regorafenib-associated HFSR in pediatric oncology.
• It suggests that proactive management can mitigate severe side effects and maintain treatment continuity.
• Further research into standardized pediatric HFSR guidelines for regorafenib and other chemotherapies is warranted.